Scarica l'app Stockscreener
286.74
0.39%
1.10
Dopo l'orario di chiusura:
286.00
-0.74
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.
Which Healthcare ETF Is the Better Buy: iShares’ Global IXJ or First Trust’s Biotech FBT? - The Motley Fool
Should You Invest in the iShares U.S. Healthcare ETF (IYH)? - Zacks Investment Research
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy - The Motley Fool
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? - Zacks Investment Research
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Vanguard Health Care ETF vs iShares U.S. Healthcare ETF - The Motley Fool
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3? - Zacks Investment Research
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research
Abbvie, Vertex lead $32B September biopharma M&A surge - BioWorld News
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
AbbVie stock: Cantor lifts target for AbbVie stock from USD 285 to USD 290 - ad-hoc-news.de
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
AbbVie Inc. (ABBV80.BK) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie (ABBV) Unveils Phase 2a Crohn's Data And Flags 2026 ESMO Readouts - Yahoo Finance
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - The Globe and Mail
AbbVie stock: At 1.84 percent below its 52-week high, AbbVie stock trades at EUR 255.05 - ad-hoc-news.de
AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying? - Yahoo Finance
Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch - Zacks Investment Research
AbbVie ABBV-466 Achieves 40.5% Crohn's Remission - grafa.com
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - TradingView
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - Zacks Investment Research
Zacks Market Edge Highlights: Palantir Technologies, BP, Palo Alto Networks, Visa and AbbVie - TradingView
AbbVie (ABBV) Reports Promising Phase 2a Data for ABBV-466 in Cr - GuruFocus
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It - The Motley Fool
AbbVie (ABBV) to Showcase Expanded Solid Tumor Research at ESMO Congress - GuruFocus
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors? - Yahoo Finance
Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle - The Motley Fool
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - Yahoo Finance
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends - The Motley Fool
Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment? - Yahoo Finance
AbbVie vs. Merck: Which Pharma Stock Offers Better Value? - Yahoo Finance
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive? - Yahoo Finance
5 Stock Ideas for Your Short List - TradingView
5 Stock Ideas for Your Short List - Zacks Investment Research
Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00 - ad-hoc-news.de
AI Stocks Lose Steam as Capital Rotates — Eli Lilly, AbbVie Near Record Highs - BigGo Finance
Form 4 AbbVie Inc For: 16 October By Investing.com - Investing.com Nigeria
AbbVie (ABBV) Stock Could Be 44% Undervalued As Cancer Trial News Lands - Yahoo Finance
Breaking Down The Big 3 Investing Strategies - Zacks Investment Research
Abbvie Inc. Announces Appointment of John M. Carethers as Director and Member of Public Policy and Sustainability Committee - www.marketscreener.com
The Dividend Divide: Pure Dividend Strategy ETF Meets Tech-Driven Growth ETF - The Motley Fool
Bristol, AbbVie Seek Intervention in Suit Over Drug Rebate Pilot - Bloomberg Law News
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
0.94%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):